Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, today announced that four renowned cancer centers have adopted the company’s short hairpin RNA (shRNAmir) technology to aid in the identification of advanced cancer treatment options. Duke University, the National Institutes of Health’s National Cancer Institute, Lee Moffitt Cancer Center and Fox Chase Cancer Center have invested in human and/or mouse shRNAmir whole genome libraries to accelerate research related to cancer biology and drug discovery.
